华润双鹤2家子公司药品补充申请及上市申请获批

财中社
16 Apr

4月16日,华润双鹤(600062)发布公告,近日全资子公司华润紫竹药业有限公司收到国家药品监督管理局颁发的盐酸奥洛他定滴眼液的《药品补充申请批准通知书》。该药品的上市许可持有人由南京恒道医药科技股份有限公司变更为华润紫竹,相关地址也随之更新。同时,控股子公司浙江新赛科药业有限公司也获得了非诺贝特酸胆碱原料药的《化学原料药上市申请批准通知书》。该原料药主要用于调节血脂,申请于2023年11月提交,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10